TY - JOUR
T1 - Analysis of the ATR-Chk1 and ATM- Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
AU - Di Benedetto, Anna
AU - Ercolani, Cristiana
AU - Mottolese, Marcella
AU - Sperati, Francesca
AU - Pizzuti, Laura
AU - Vici, Patrizia
AU - Terrenato, Irene
AU - Shaaban, Abeer M.
AU - Humphries, Matthew P.
AU - Di Lauro, Luigi
AU - Barba, Maddalena
AU - Vitale, Ilio
AU - Ciliberto, Gennaro
AU - Speirs, Valerie
AU - De Maria Marchiano, Ruggero
AU - Maugeri-Saccà, Marcello
PY - 2017
Y1 - 2017
N2 - The ATR-Chk1 and ATM-Chk2 pathways are central in DNA damage repair (DDR) and their over- activation may confer aggressive molecular features, being an adaptive response to endogenous DNA damage and oncogene-induced replication stress. Herein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC). The expression of DDR kinases (pATR, pATM, pChk1, pChk2, and pWee1) and DNA damage markers (pRPA32 and γ-H2AX) was evaluated by immunohistochemistry in 289 MBC samples to assess their association. Survival analyses were carried out in 112 patients. Survival curves were estimated with the Kaplan-Meier method and compared by log-rank test. Cox proportional regression models were generated to identify variables impacting survival outcomes. The expression of pATR conferred poorer survival outcomes (log rank p = 0.013, p = 0.007 and p = 0.010
for overall, 15- and 10-year survival, respectively). Multivariate Cox models of 10-year survival and overall indicated that pATR expression, alone or combined with pChk2, was an independent predictor of adverse outcomes (10-year survival: pATR: HR 2.74, 95% CI: 1.23–6.10; pATR/pChk2: HR 2.92, 95% CI: 1.35–6.33; overall survival: pATR: HR 2.58, 95% CI: 1.20–5.53; pATR/pChk2: HR 2.89, 95% CI: 1.37– 6.12). Overall, the ATR/ATM-initiated molecular cascade seems to be active in a fraction of MBC patients and may represent a negative prognostic factor.
AB - The ATR-Chk1 and ATM-Chk2 pathways are central in DNA damage repair (DDR) and their over- activation may confer aggressive molecular features, being an adaptive response to endogenous DNA damage and oncogene-induced replication stress. Herein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC). The expression of DDR kinases (pATR, pATM, pChk1, pChk2, and pWee1) and DNA damage markers (pRPA32 and γ-H2AX) was evaluated by immunohistochemistry in 289 MBC samples to assess their association. Survival analyses were carried out in 112 patients. Survival curves were estimated with the Kaplan-Meier method and compared by log-rank test. Cox proportional regression models were generated to identify variables impacting survival outcomes. The expression of pATR conferred poorer survival outcomes (log rank p = 0.013, p = 0.007 and p = 0.010
for overall, 15- and 10-year survival, respectively). Multivariate Cox models of 10-year survival and overall indicated that pATR expression, alone or combined with pChk2, was an independent predictor of adverse outcomes (10-year survival: pATR: HR 2.74, 95% CI: 1.23–6.10; pATR/pChk2: HR 2.92, 95% CI: 1.35–6.33; overall survival: pATR: HR 2.58, 95% CI: 1.20–5.53; pATR/pChk2: HR 2.89, 95% CI: 1.37– 6.12). Overall, the ATR/ATM-initiated molecular cascade seems to be active in a fraction of MBC patients and may represent a negative prognostic factor.
KW - ATR expression
KW - ATR expression
UR - http://hdl.handle.net/10807/111225
U2 - 10.1038/s41598-017-07366-7
DO - 10.1038/s41598-017-07366-7
M3 - Article
SN - 2045-2322
SP - N/A-N/A
JO - Scientific Reports
JF - Scientific Reports
ER -
